The genetics company is closing a unit that was once seen as core to its future.

A new study led by Genomics England and Queen Mary University of London estimates that genetic testing could identify ...

Recent advances in genetic testing technology have transformed personal health care from general guidelines to precise, ...

focusing instead on selling genetic tests to consumers and using the resulting data for research. In closing its therapeutics ...

23andMe currently lists two assets in early-stage testing. First ... The dual-mechanism drug targets ULBP6, which is secreted ...

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Ibuprofen counters problems caused by mutations in the MAN1B1 gene, fruit fly tests show. Early results in three children are ”fairly positive.” ...

Google DeepMind releases AlphaFold 3's source code to academics, marking a significant advance in AI-powered molecular biology and drug discovery, while balancing open science with commercial ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

When the two drugs were given in combination, it led to lasting tumor regression without the development of resistance. In healthy human cells, DNA is neatly packaged into bundles called chromosomes.